ストックスクリーナーアプリを入手
0.7677
5.64%
0.041
前日終値:
$0.7267
開ける：
$0.7315
24時間の取引高:
1.42M
Relative Volume:
0.87
時価総額：
$93.31M
収益：
$257.24M
当期純損益:
$-237.89M
株価収益率:
-0.2953
EPS:
-2.6
ネットキャッシュフロー:
$-175.17M
1週間 パフォーマンス:
+1.28%
1か月 パフォーマンス:
+1.53%
6か月 パフォーマンス:
-47.78%
1年 パフォーマンス:
-52.90%
1日の値動き範囲:
$0.7315
$0.7695
1週間の範囲:
$0.71
$0.77
52週間の値動き範囲:
$0.6603
$2.43
Coherus Oncology Inc Stock (CHRS) Company Profile
名前
Coherus Oncology Inc
セクター
電話
(650) 649-3530
住所
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
CHRS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
0.7677 | 93.31M | 257.24M | -237.89M | -175.17M | -2.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-16 | ダウングレード | UBS | Buy → Neutral |
| 2023-11-17 | 開始されました | Robert W. Baird | Outperform |
| 2023-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2023-07-24 | 開始されました | Citigroup | Buy |
| 2023-05-01 | 開始されました | Truist | Buy |
| 2023-03-28 | アップグレード | UBS | Neutral → Buy |
| 2022-06-14 | 開始されました | UBS | Neutral |
| 2022-03-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-16 | 開始されました | BofA Securities | Neutral |
| 2020-04-17 | 開始されました | SunTrust | Buy |
| 2019-08-13 | 開始されました | Mizuho | Buy |
| 2019-08-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-08-02 | 繰り返されました | Maxim Group | Buy |
| 2019-06-11 | 開始されました | Barclays | Overweight |
| 2019-05-07 | 開始されました | H.C. Wainwright | Buy |
| 2018-08-28 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-09 | 繰り返されました | Maxim Group | Buy |
| 2017-08-08 | 繰り返されました | JP Morgan | Overweight |
| 2017-06-13 | 繰り返されました | Maxim Group | Buy |
| 2017-05-05 | 開始されました | BMO Capital Markets | Outperform |
| 2016-10-19 | 開始されました | Robert W. Baird | Outperform |
| 2016-09-07 | 開始されました | Maxim Group | Buy |
| 2016-07-27 | 開始されました | Citigroup | Buy |
| 2016-01-20 | 開始されました | Credit Suisse | Outperform |
すべてを表示
Coherus Oncology Inc (CHRS) 最新ニュース
Coherus Oncology reports annual meeting results By Investing.com - Investing.com Canada
Coherus Oncology reports annual meeting results - Investing.com
Coherus Biosciences Holds Virtual Annual Stockholder Meeting - TipRanks
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory - Insider Monkey
Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus - Investing.com
Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
Genocea Biosciences (NASDAQ:GNCAQ) vs. Coherus BioSciences (NASDAQ:CHRS) Critical Survey - Defense World
Coherus Oncology (CHRS) Shifts Focus with New Name and Innovativ - GuruFocus
Coherus Biosciences Rebrands to Coherus Oncology - TipRanks
Coherus Completes Strategic Transformation to Coherus Oncology, - GuruFocus
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | CHRS Stock News - GuruFocus
Coherus Completes Strategic Transformation To Coherus Oncology - marketscreener.com
Coherus Completes Strategic Transformation to Coherus - GlobeNewswire
Coherus Makes Bold Strategic Shift: Rebrands as Cancer-Focused Powerhouse with 3 Novel Immunotherapies - Stock Titan
Coherus Oncology (CHRS) Shifts Focus with New Name and Innovative Therapies | CHRS Stock News - GuruFocus
First patient dosed in STORM-Coherus cancer alliance - Business Weekly
Coherus BioSciences at 6th Annual Oncology Summit: Strategic Shift to Innovation - Investing.com Canada
Coherus BioSciences, Inc. Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI®? (toripalimab-Ttzi) - marketscreener.com
Coherus BioSciences (CHRS) Engages in New Cancer Treatment Colla - GuruFocus
Coherus BioSciences (CHRS) Engages in New Cancer Treatment Collaboration | CHRS Stock News - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) | CHRS Stock News - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times
Coherus Announces Clinical Collaboration with STORM - GlobeNewswire
Breakthrough Cancer Trial Launches: LOQTORZI Combination Study Targets 4 Major Cancer Types - Stock Titan
Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles By Investing.com - Investing.com Canada
Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles - Investing.com
StockNews.com Downgrades Coherus BioSciences (NASDAQ:CHRS) to Sell - Defense World
The Manufacturers Life Insurance Company Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Coherus BioSciences, Inc.'s (NASDAQ:CHRS) 32% Dip In Price Shows Sentiment Is Matching Revenues - simplywall.st
Coherus BioSciences Earnings Call Highlights Transition and Growth - TipRanks
Some Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Just Made A Major Cut To Next Year's Estimates - simplywall.st
Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates - MSN
Coherus BioSciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update | CHRS Stock News - GuruFocus
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2025 Earnings Call Transcript - Insider Monkey
Coherus BioSciences Q1 2025 Earnings Call Transcript - MarketBeat
Coherus BioSciences Inc (CHRS) Q1 2025 Earnings Call Highlights: Strategic Growth and ... - Yahoo Finance
Wells Fargo & Company MN Has $85,000 Stock Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
Coherus BioSciences: Q1 2025 Financial Highlights and Strategic Shift - TipRanks
Coherus BioSciences (CHRS) Focuses on Oncology After Divestitures - GuruFocus
Earnings call transcript: Coherus BioSciences sees flat revenue, stock slides post-Q1 2025 - Investing.com Nigeria
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - ADVFN
Coherus BioSciences Inc Reports Q1 2025 Results: EPS of $(0.41) Misses Estimate, Revenue at $7.6 Million Falls Short - GuruFocus
Coherus BioSciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Coherus BioSciences (CHRS) Reports Q1 Revenue Surge, Faces Share Decline - GuruFocus
Coherus BioSciences: Q1 Earnings Snapshot - San Antonio Express-News
Coherus BioSciences Reports Q1 2025 Financial Results and Advances Oncology Portfolio with CHS-114 and LOQTORZI Developments - Nasdaq
Coherus Oncology Inc (CHRS) 財務データ
収益
当期純利益
現金流量
EPS
0.29%
大文字化:
|
ボリューム (24 時間):